Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) Stock Competitors & Peer Comparison
See (AXSM) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AXSM | $101.17 | +0.34% | 4.9B | -17.41 | -$5.77 | N/A |
| VRTX | $464.66 | -1.06% | 118.3B | -121.27 | -$3.80 | N/A |
| REGN | $555.52 | -1.35% | 59.3B | 14.19 | $39.36 | +0.31% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $325.57 | -0.99% | 42.4B | -154.67 | -$2.10 | N/A |
| ARGX | $597.93 | +1.00% | 36.4B | 36.29 | $16.40 | N/A |
| BNTX | $111.80 | -3.04% | 27.1B | -30.03 | -$3.76 | N/A |
| RPRX | $37.12 | +1.23% | 20.8B | 15.13 | $2.45 | +2.32% |
| SMMT | $27.17 | -5.23% | 20.4B | -80.74 | -$0.34 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
Stock Comparison
AXSM vs VRTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, VRTX has a market cap of 118.3B. Regarding current trading prices, AXSM is priced at $101.17, while VRTX trades at $464.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas VRTX's P/E ratio is -121.27. In terms of profitability, AXSM's ROE is -3.64%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, AXSM is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check VRTX's competition here
AXSM vs REGN Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, REGN has a market cap of 59.3B. Regarding current trading prices, AXSM is priced at $101.17, while REGN trades at $555.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas REGN's P/E ratio is 14.19. In terms of profitability, AXSM's ROE is -3.64%, compared to REGN's ROE of +0.15%. Regarding short-term risk, AXSM is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check REGN's competition here
AXSM vs SGEN Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, AXSM is priced at $101.17, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas SGEN's P/E ratio is -57.19. In terms of profitability, AXSM's ROE is -3.64%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, AXSM is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check SGEN's competition here
AXSM vs ALNY Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ALNY has a market cap of 42.4B. Regarding current trading prices, AXSM is priced at $101.17, while ALNY trades at $325.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ALNY's P/E ratio is -154.67. In terms of profitability, AXSM's ROE is -3.64%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, AXSM is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ALNY's competition here
AXSM vs ARGX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ARGX has a market cap of 36.4B. Regarding current trading prices, AXSM is priced at $101.17, while ARGX trades at $597.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ARGX's P/E ratio is 36.29. In terms of profitability, AXSM's ROE is -3.64%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, AXSM and ARGX have similar daily volatility (1.32).Check ARGX's competition here
AXSM vs BNTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, BNTX has a market cap of 27.1B. Regarding current trading prices, AXSM is priced at $101.17, while BNTX trades at $111.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas BNTX's P/E ratio is -30.03. In terms of profitability, AXSM's ROE is -3.64%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, AXSM is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check BNTX's competition here
AXSM vs RPRX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, AXSM is priced at $101.17, while RPRX trades at $37.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RPRX's P/E ratio is 15.13. In terms of profitability, AXSM's ROE is -3.64%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, AXSM is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check RPRX's competition here
AXSM vs SMMT Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, SMMT has a market cap of 20.4B. Regarding current trading prices, AXSM is priced at $101.17, while SMMT trades at $27.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas SMMT's P/E ratio is -80.74. In terms of profitability, AXSM's ROE is -3.64%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, AXSM is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check SMMT's competition here
AXSM vs BGNE Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, AXSM is priced at $101.17, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas BGNE's P/E ratio is -22.55. In terms of profitability, AXSM's ROE is -3.64%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, AXSM is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check BGNE's competition here
AXSM vs DNA-WT Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, AXSM is priced at $101.17, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, AXSM's ROE is -3.64%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, AXSM is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check DNA-WT's competition here
AXSM vs GMAB Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, GMAB has a market cap of 14.2B. Regarding current trading prices, AXSM is priced at $101.17, while GMAB trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas GMAB's P/E ratio is 13.58. In terms of profitability, AXSM's ROE is -3.64%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, AXSM is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check GMAB's competition here
AXSM vs INCY Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, AXSM is priced at $101.17, while INCY trades at $74.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas INCY's P/E ratio is 350.80. In terms of profitability, AXSM's ROE is -3.64%, compared to INCY's ROE of +0.01%. Regarding short-term risk, AXSM is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check INCY's competition here
AXSM vs UTHR Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, UTHR has a market cap of 13.4B. Regarding current trading prices, AXSM is priced at $101.17, while UTHR trades at $300.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas UTHR's P/E ratio is 11.88. In terms of profitability, AXSM's ROE is -3.64%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, AXSM is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check UTHR's competition here
AXSM vs MRNA Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MRNA has a market cap of 13.1B. Regarding current trading prices, AXSM is priced at $101.17, while MRNA trades at $32.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MRNA's P/E ratio is -3.88. In terms of profitability, AXSM's ROE is -3.64%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, AXSM is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check MRNA's competition here
AXSM vs KRTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, AXSM is priced at $101.17, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas KRTX's P/E ratio is -28.09. In terms of profitability, AXSM's ROE is -3.64%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, AXSM is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check KRTX's competition here
AXSM vs EXEL Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, EXEL has a market cap of 12.1B. Regarding current trading prices, AXSM is priced at $101.17, while EXEL trades at $37.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas EXEL's P/E ratio is 20.27. In terms of profitability, AXSM's ROE is -3.64%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, AXSM is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check EXEL's competition here
AXSM vs BMRN Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, AXSM is priced at $101.17, while BMRN trades at $58.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas BMRN's P/E ratio is 21.53. In terms of profitability, AXSM's ROE is -3.64%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, AXSM and BMRN have similar daily volatility (1.32).Check BMRN's competition here
AXSM vs ASND Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ASND has a market cap of 9.9B. Regarding current trading prices, AXSM is priced at $101.17, while ASND trades at $163.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ASND's P/E ratio is -24.04. In terms of profitability, AXSM's ROE is -3.64%, compared to ASND's ROE of +1.91%. Regarding short-term risk, AXSM is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ASND's competition here
AXSM vs RXDX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, AXSM is priced at $101.17, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RXDX's P/E ratio is -56.47. In terms of profitability, AXSM's ROE is -3.64%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, AXSM is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check RXDX's competition here
AXSM vs TECH Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, AXSM is priced at $101.17, while TECH trades at $58.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas TECH's P/E ratio is 70.54. In terms of profitability, AXSM's ROE is -3.64%, compared to TECH's ROE of +0.06%. Regarding short-term risk, AXSM is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check TECH's competition here
AXSM vs VRNA Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, AXSM is priced at $101.17, while VRNA trades at $105.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas VRNA's P/E ratio is -52.54. In terms of profitability, AXSM's ROE is -3.64%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, AXSM is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check VRNA's competition here
AXSM vs BBIO Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, AXSM is priced at $101.17, while BBIO trades at $46.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas BBIO's P/E ratio is -12.99. In terms of profitability, AXSM's ROE is -3.64%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, AXSM is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check BBIO's competition here
AXSM vs IMGN Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, AXSM is priced at $101.17, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas IMGN's P/E ratio is -111.55. In terms of profitability, AXSM's ROE is -3.64%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, AXSM is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check IMGN's competition here
AXSM vs BPMC Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, AXSM is priced at $101.17, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas BPMC's P/E ratio is -51.58. In terms of profitability, AXSM's ROE is -3.64%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, AXSM is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check BPMC's competition here
AXSM vs CERE Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, AXSM is priced at $101.17, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CERE's P/E ratio is -16.47. In terms of profitability, AXSM's ROE is -3.64%, compared to CERE's ROE of -0.43%. Regarding short-term risk, AXSM is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check CERE's competition here
AXSM vs ROIVW Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, AXSM is priced at $101.17, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, AXSM's ROE is -3.64%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, AXSM is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ROIVW's competition here
AXSM vs ROIV Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, AXSM is priced at $101.17, while ROIV trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ROIV's P/E ratio is -15.13. In terms of profitability, AXSM's ROE is -3.64%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, AXSM is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check ROIV's competition here
AXSM vs CORT Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, AXSM is priced at $101.17, while CORT trades at $68.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CORT's P/E ratio is 60.13. In terms of profitability, AXSM's ROE is -3.64%, compared to CORT's ROE of +0.20%. Regarding short-term risk, AXSM is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check CORT's competition here
AXSM vs HALO Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, HALO has a market cap of 7.1B. Regarding current trading prices, AXSM is priced at $101.17, while HALO trades at $58.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas HALO's P/E ratio is 15.35. In terms of profitability, AXSM's ROE is -3.64%, compared to HALO's ROE of +1.22%. Regarding short-term risk, AXSM is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check HALO's competition here
AXSM vs JAZZ Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, AXSM is priced at $101.17, while JAZZ trades at $115.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas JAZZ's P/E ratio is 15.93. In terms of profitability, AXSM's ROE is -3.64%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, AXSM is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check JAZZ's competition here
AXSM vs RVMD Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, AXSM is priced at $101.17, while RVMD trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RVMD's P/E ratio is -9.29. In terms of profitability, AXSM's ROE is -3.64%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, AXSM is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check RVMD's competition here
AXSM vs RETA Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, AXSM is priced at $101.17, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RETA's P/E ratio is -66.29. In terms of profitability, AXSM's ROE is -3.64%, compared to RETA's ROE of +0.47%. Regarding short-term risk, AXSM is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check RETA's competition here
AXSM vs IONS Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, AXSM is priced at $101.17, while IONS trades at $41.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas IONS's P/E ratio is -13.77. In terms of profitability, AXSM's ROE is -3.64%, compared to IONS's ROE of -0.92%. Regarding short-term risk, AXSM is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check IONS's competition here
AXSM vs MDGL Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MDGL has a market cap of 6.5B. Regarding current trading prices, AXSM is priced at $101.17, while MDGL trades at $296.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MDGL's P/E ratio is -16.49. In terms of profitability, AXSM's ROE is -3.64%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, AXSM is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check MDGL's competition here
AXSM vs AMRN Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, AMRN has a market cap of 6.2B. Regarding current trading prices, AXSM is priced at $101.17, while AMRN trades at $14.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas AMRN's P/E ratio is -3.41. In terms of profitability, AXSM's ROE is -3.64%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, AXSM is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check AMRN's competition here
AXSM vs NUVL Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, NUVL has a market cap of 5.9B. Regarding current trading prices, AXSM is priced at $101.17, while NUVL trades at $81.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas NUVL's P/E ratio is -18.55. In terms of profitability, AXSM's ROE is -3.64%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, AXSM is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check NUVL's competition here
AXSM vs TGTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, AXSM is priced at $101.17, while TGTX trades at $36.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas TGTX's P/E ratio is 143.96. In terms of profitability, AXSM's ROE is -3.64%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, AXSM is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check TGTX's competition here
AXSM vs RYTM Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, AXSM is priced at $101.17, while RYTM trades at $85.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RYTM's P/E ratio is -30.60. In terms of profitability, AXSM's ROE is -3.64%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, AXSM is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check RYTM's competition here
AXSM vs ABCM Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, AXSM is priced at $101.17, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, AXSM's ROE is -3.64%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, AXSM is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check ABCM's competition here
AXSM vs ISEE Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, AXSM is priced at $101.17, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ISEE's P/E ratio is -22.44. In terms of profitability, AXSM's ROE is -3.64%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, AXSM is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check ISEE's competition here
AXSM vs CRSP Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, AXSM is priced at $101.17, while CRSP trades at $60.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CRSP's P/E ratio is -14.20. In terms of profitability, AXSM's ROE is -3.64%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, AXSM is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check CRSP's competition here
AXSM vs MRUS Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, AXSM is priced at $101.17, while MRUS trades at $65.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MRUS's P/E ratio is -15.77. In terms of profitability, AXSM's ROE is -3.64%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, AXSM is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check MRUS's competition here
AXSM vs TLX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, TLX has a market cap of 4.7B. Regarding current trading prices, AXSM is priced at $101.17, while TLX trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas TLX's P/E ratio is 139.60. In terms of profitability, AXSM's ROE is -3.64%, compared to TLX's ROE of +0.06%. Regarding short-term risk, AXSM is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check TLX's competition here
AXSM vs PCVX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, PCVX has a market cap of 4.6B. Regarding current trading prices, AXSM is priced at $101.17, while PCVX trades at $35.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas PCVX's P/E ratio is -8.99. In terms of profitability, AXSM's ROE is -3.64%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, AXSM is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check PCVX's competition here
AXSM vs SLNO Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, SLNO has a market cap of 4.5B. Regarding current trading prices, AXSM is priced at $101.17, while SLNO trades at $85.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas SLNO's P/E ratio is -17.99. In terms of profitability, AXSM's ROE is -3.64%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, AXSM is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check SLNO's competition here
AXSM vs ALPN Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, AXSM is priced at $101.17, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ALPN's P/E ratio is -101.52. In terms of profitability, AXSM's ROE is -3.64%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, AXSM is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check ALPN's competition here
AXSM vs KRYS Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, AXSM is priced at $101.17, while KRYS trades at $153.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas KRYS's P/E ratio is 36.58. In terms of profitability, AXSM's ROE is -3.64%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, AXSM is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check KRYS's competition here
AXSM vs CYTK Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, AXSM is priced at $101.17, while CYTK trades at $36.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CYTK's P/E ratio is -6.92. In terms of profitability, AXSM's ROE is -3.64%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, AXSM is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check CYTK's competition here
AXSM vs ALKS Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ALKS has a market cap of 4.3B. Regarding current trading prices, AXSM is priced at $101.17, while ALKS trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ALKS's P/E ratio is 12.46. In terms of profitability, AXSM's ROE is -3.64%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, AXSM is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ALKS's competition here
AXSM vs ADMA Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, AXSM is priced at $101.17, while ADMA trades at $18.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ADMA's P/E ratio is 21.43. In terms of profitability, AXSM's ROE is -3.64%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, AXSM is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ADMA's competition here
AXSM vs ZLAB Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ZLAB has a market cap of 4.3B. Regarding current trading prices, AXSM is priced at $101.17, while ZLAB trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ZLAB's P/E ratio is -15.48. In terms of profitability, AXSM's ROE is -3.64%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, AXSM is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ZLAB's competition here
AXSM vs ABVX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ABVX has a market cap of 4.2B. Regarding current trading prices, AXSM is priced at $101.17, while ABVX trades at $69.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ABVX's P/E ratio is -19.18. In terms of profitability, AXSM's ROE is -3.64%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, AXSM is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ABVX's competition here
AXSM vs OPT Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, AXSM is priced at $101.17, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas OPT's P/E ratio is -1.52. In terms of profitability, AXSM's ROE is -3.64%, compared to OPT's ROE of +2.60%. Regarding short-term risk, AXSM is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check OPT's competition here
AXSM vs RNA Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RNA has a market cap of 4.2B. Regarding current trading prices, AXSM is priced at $101.17, while RNA trades at $34.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RNA's P/E ratio is -11.52. In terms of profitability, AXSM's ROE is -3.64%, compared to RNA's ROE of -0.27%. Regarding short-term risk, AXSM is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check RNA's competition here
AXSM vs MTSR Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MTSR has a market cap of 4.1B. Regarding current trading prices, AXSM is priced at $101.17, while MTSR trades at $36.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MTSR's P/E ratio is -15.58. In terms of profitability, AXSM's ROE is -3.64%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, AXSM is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check MTSR's competition here
AXSM vs MRTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, AXSM is priced at $101.17, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MRTX's P/E ratio is -4.82. In terms of profitability, AXSM's ROE is -3.64%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, AXSM is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check MRTX's competition here
AXSM vs AKRO Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, AXSM is priced at $101.17, while AKRO trades at $49.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas AKRO's P/E ratio is -13.13. In terms of profitability, AXSM's ROE is -3.64%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, AXSM is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check AKRO's competition here
AXSM vs ACLX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, AXSM is priced at $101.17, while ACLX trades at $70.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ACLX's P/E ratio is -23.61. In terms of profitability, AXSM's ROE is -3.64%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, AXSM is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ACLX's competition here
AXSM vs LEGN Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, AXSM is priced at $101.17, while LEGN trades at $41.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas LEGN's P/E ratio is -35.18. In terms of profitability, AXSM's ROE is -3.64%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, AXSM is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check LEGN's competition here
AXSM vs ACAD Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, AXSM is priced at $101.17, while ACAD trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ACAD's P/E ratio is 16.51. In terms of profitability, AXSM's ROE is -3.64%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, AXSM is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ACAD's competition here
AXSM vs RYZB Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, AXSM is priced at $101.17, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RYZB's P/E ratio is -57.86. In terms of profitability, AXSM's ROE is -3.64%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, AXSM is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check RYZB's competition here
AXSM vs VKTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, AXSM is priced at $101.17, while VKTX trades at $33.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas VKTX's P/E ratio is -21.56. In terms of profitability, AXSM's ROE is -3.64%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, AXSM is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check VKTX's competition here
AXSM vs CBAY Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, AXSM is priced at $101.17, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CBAY's P/E ratio is -32.81. In terms of profitability, AXSM's ROE is -3.64%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, AXSM is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check CBAY's competition here
AXSM vs AAPG Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, AAPG has a market cap of 3.6B. Regarding current trading prices, AXSM is priced at $101.17, while AAPG trades at $39.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas AAPG's P/E ratio is -52.39. In terms of profitability, AXSM's ROE is -3.64%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, AXSM is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check AAPG's competition here
AXSM vs SWTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, AXSM is priced at $101.17, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas SWTX's P/E ratio is -13.78. In terms of profitability, AXSM's ROE is -3.64%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, AXSM is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check SWTX's competition here
AXSM vs SRRK Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, AXSM is priced at $101.17, while SRRK trades at $37.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas SRRK's P/E ratio is -14.55. In terms of profitability, AXSM's ROE is -3.64%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, AXSM is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check SRRK's competition here
AXSM vs PTCT Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, PTCT has a market cap of 3.5B. Regarding current trading prices, AXSM is priced at $101.17, while PTCT trades at $49.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas PTCT's P/E ratio is 6.81. In terms of profitability, AXSM's ROE is -3.64%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, AXSM is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check PTCT's competition here
AXSM vs PTGX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, AXSM is priced at $101.17, while PTGX trades at $56.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas PTGX's P/E ratio is 72.14. In terms of profitability, AXSM's ROE is -3.64%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, AXSM is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check PTGX's competition here
AXSM vs MLTX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, AXSM is priced at $101.17, while MLTX trades at $53.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MLTX's P/E ratio is -23.68. In terms of profitability, AXSM's ROE is -3.64%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, AXSM is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check MLTX's competition here
AXSM vs KYMR Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, AXSM is priced at $101.17, while KYMR trades at $44.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas KYMR's P/E ratio is -14.21. In terms of profitability, AXSM's ROE is -3.64%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, AXSM is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check KYMR's competition here
AXSM vs IMVT Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, IMVT has a market cap of 2.9B. Regarding current trading prices, AXSM is priced at $101.17, while IMVT trades at $16.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas IMVT's P/E ratio is -6.14. In terms of profitability, AXSM's ROE is -3.64%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, AXSM is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check IMVT's competition here
AXSM vs MORF Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, AXSM is priced at $101.17, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MORF's P/E ratio is -14.88. In terms of profitability, AXSM's ROE is -3.64%, compared to MORF's ROE of -0.22%. Regarding short-term risk, AXSM is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check MORF's competition here
AXSM vs MOR Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, AXSM is priced at $101.17, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MOR's P/E ratio is -12.64. In terms of profitability, AXSM's ROE is -3.64%, compared to MOR's ROE of -1.84%. Regarding short-term risk, AXSM is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check MOR's competition here
AXSM vs CRNX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, AXSM is priced at $101.17, while CRNX trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CRNX's P/E ratio is -7.97. In terms of profitability, AXSM's ROE is -3.64%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, AXSM is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check CRNX's competition here
AXSM vs NAMSW Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, NAMSW has a market cap of 2.7B. Regarding current trading prices, AXSM is priced at $101.17, while NAMSW trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas NAMSW's P/E ratio is N/A. In terms of profitability, AXSM's ROE is -3.64%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, AXSM is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check NAMSW's competition here
AXSM vs KDNY Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, AXSM is priced at $101.17, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas KDNY's P/E ratio is -12.47. In terms of profitability, AXSM's ROE is -3.64%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, AXSM is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check KDNY's competition here
AXSM vs RXRX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RXRX has a market cap of 2.7B. Regarding current trading prices, AXSM is priced at $101.17, while RXRX trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RXRX's P/E ratio is -3.51. In terms of profitability, AXSM's ROE is -3.64%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, AXSM is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check RXRX's competition here
AXSM vs NAMS Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, AXSM is priced at $101.17, while NAMS trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas NAMS's P/E ratio is -12.73. In terms of profitability, AXSM's ROE is -3.64%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, AXSM is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check NAMS's competition here
AXSM vs MYOV Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, AXSM is priced at $101.17, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MYOV's P/E ratio is -14.05. In terms of profitability, AXSM's ROE is -3.64%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, AXSM is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check MYOV's competition here
AXSM vs RARE Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, AXSM is priced at $101.17, while RARE trades at $28.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas RARE's P/E ratio is -4.74. In terms of profitability, AXSM's ROE is -3.64%, compared to RARE's ROE of -1.86%. Regarding short-term risk, AXSM is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check RARE's competition here
AXSM vs LGND Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, AXSM is priced at $101.17, while LGND trades at $135.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas LGND's P/E ratio is -18.51. In terms of profitability, AXSM's ROE is -3.64%, compared to LGND's ROE of -0.16%. Regarding short-term risk, AXSM is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check LGND's competition here
AXSM vs MIRM Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, AXSM is priced at $101.17, while MIRM trades at $52.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas MIRM's P/E ratio is -31.98. In terms of profitability, AXSM's ROE is -3.64%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, AXSM is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check MIRM's competition here
AXSM vs CPRX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, AXSM is priced at $101.17, while CPRX trades at $21.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CPRX's P/E ratio is 13.25. In terms of profitability, AXSM's ROE is -3.64%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, AXSM is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check CPRX's competition here
AXSM vs XENE Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, AXSM is priced at $101.17, while XENE trades at $31.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas XENE's P/E ratio is -9.62. In terms of profitability, AXSM's ROE is -3.64%, compared to XENE's ROE of -0.32%. Regarding short-term risk, AXSM is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check XENE's competition here
AXSM vs PRVB Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, AXSM is priced at $101.17, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas PRVB's P/E ratio is -16.43. In terms of profitability, AXSM's ROE is -3.64%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, AXSM is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check PRVB's competition here
AXSM vs APGE Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, APGE has a market cap of 2.4B. Regarding current trading prices, AXSM is priced at $101.17, while APGE trades at $39.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas APGE's P/E ratio is -10.99. In terms of profitability, AXSM's ROE is -3.64%, compared to APGE's ROE of -0.19%. Regarding short-term risk, AXSM is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check APGE's competition here
AXSM vs APLS Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, APLS has a market cap of 2.4B. Regarding current trading prices, AXSM is priced at $101.17, while APLS trades at $19.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas APLS's P/E ratio is -10.41. In terms of profitability, AXSM's ROE is -3.64%, compared to APLS's ROE of -1.00%. Regarding short-term risk, AXSM is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check APLS's competition here
AXSM vs LBPH Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, AXSM is priced at $101.17, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas LBPH's P/E ratio is -26.66. In terms of profitability, AXSM's ROE is -3.64%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, AXSM is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check LBPH's competition here
AXSM vs IBRX Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, AXSM is priced at $101.17, while IBRX trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas IBRX's P/E ratio is -4.65. In terms of profitability, AXSM's ROE is -3.64%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, AXSM is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check IBRX's competition here
AXSM vs DICE Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, AXSM is priced at $101.17, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas DICE's P/E ratio is -21.91. In terms of profitability, AXSM's ROE is -3.64%, compared to DICE's ROE of +0.56%. Regarding short-term risk, AXSM is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for AXSM.Check DICE's competition here
AXSM vs ARWR Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, AXSM is priced at $101.17, while ARWR trades at $16.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas ARWR's P/E ratio is -13.06. In terms of profitability, AXSM's ROE is -3.64%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, AXSM is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check ARWR's competition here
AXSM vs IDYA Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, AXSM is priced at $101.17, while IDYA trades at $25.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas IDYA's P/E ratio is -6.85. In terms of profitability, AXSM's ROE is -3.64%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, AXSM is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check IDYA's competition here
AXSM vs GLPG Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, AXSM is priced at $101.17, while GLPG trades at $32.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas GLPG's P/E ratio is -6.35. In terms of profitability, AXSM's ROE is -3.64%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, AXSM is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check GLPG's competition here
AXSM vs AGIO Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, AXSM is priced at $101.17, while AGIO trades at $37.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas AGIO's P/E ratio is 3.22. In terms of profitability, AXSM's ROE is -3.64%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, AXSM is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check AGIO's competition here
AXSM vs CALT Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, AXSM is priced at $101.17, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas CALT's P/E ratio is -22.73. In terms of profitability, AXSM's ROE is -3.64%, compared to CALT's ROE of -1.67%. Regarding short-term risk, AXSM is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check CALT's competition here
AXSM vs IMRA Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, IMRA has a market cap of 2.1B. Regarding current trading prices, AXSM is priced at $101.17, while IMRA trades at $41.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas IMRA's P/E ratio is N/A. In terms of profitability, AXSM's ROE is -3.64%, compared to IMRA's ROE of -0.41%. Regarding short-term risk, AXSM is less volatile compared to IMRA. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check IMRA's competition here
AXSM vs BEAM Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, BEAM has a market cap of 2.1B. Regarding current trading prices, AXSM is priced at $101.17, while BEAM trades at $20.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas BEAM's P/E ratio is -4.52. In terms of profitability, AXSM's ROE is -3.64%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, AXSM is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check BEAM's competition here
AXSM vs VCEL Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, AXSM is priced at $101.17, while VCEL trades at $40.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas VCEL's P/E ratio is 829.00. In terms of profitability, AXSM's ROE is -3.64%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, AXSM is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check VCEL's competition here
AXSM vs IRON Comparison July 2025
AXSM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXSM stands at 4.9B. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, AXSM is priced at $101.17, while IRON trades at $59.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXSM currently has a P/E ratio of -17.41, whereas IRON's P/E ratio is -15.29. In terms of profitability, AXSM's ROE is -3.64%, compared to IRON's ROE of -0.23%. Regarding short-term risk, AXSM is less volatile compared to IRON. This indicates potentially lower risk in terms of short-term price fluctuations for AXSM.Check IRON's competition here